According to the ESMO guidelines, what are the recommended radioligand therapy and chemotherapy regimens for an adult patient with metastatic castration‑resistant prostate cancer after androgen‑receptor pathway inhibition, and for patients with well‑differentiated neuroendocrine tumors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ESMO Guidelines for Radioligand Therapy and Chemotherapy in mCRPC and Neuroendocrine Tumors

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Radioligand Therapy: 177Lu-PSMA-617

For adult patients with progressive PSMA-positive mCRPC who have already received both an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, 177Lu-PSMA-617 is the recommended radioligand therapy according to ESMO 2023 guidelines 1.

Key Evidence and Outcomes:

  • Survival benefit: 4.0 months median OS gain (HR 0.62,95% CI 0.52-0.74) based on the VISION trial
  • ESMO-MCBS score: 4m (Form 2a) - indicating meaningful clinical benefit
  • Toxicity profile: Higher grade 3 adverse events (52.7% vs 38% in control arm)
  • Quality of life data: Still pending at time of guideline publication

Patient Selection Criteria:

  • PSMA-positive disease confirmed on imaging
  • Prior treatment with ARPI (abiraterone or enzalutamide)
  • Prior taxane-based chemotherapy (docetaxel or cabazitaxel)
  • Progressive disease despite these therapies

Important caveat: The evidence provided does not include ESMO recommendations for neuroendocrine tumors. The guidelines shown are specific to prostate cancer only.

Chemotherapy Options in mCRPC After ARPI Failure

First-Line Chemotherapy Options

Docetaxel (every 3 weeks) + Prednisone/Prednisolone

  • Indication: First-line chemotherapy for mCRPC
  • Evidence: TAX 327 trial showed 2.9 months OS gain (HR 0.79,95% CI 0.67-0.93) 1
  • Quality of life: Improved
  • ESMO-MCBS score: 3 (Form 2a)

Second-Line Chemotherapy After Docetaxel

Cabazitaxel + Prednisone/Prednisolone

This is the preferred second-line chemotherapy option, particularly when comparing against switching to another ARPI 1.

Evidence from CARD Trial (Most Relevant):
  • Comparison: Cabazitaxel vs. abiraterone or enzalutamide (alternative ARPI)
  • PFS benefit: 4.3 months gain (HR 0.54,95% CI 0.40-0.73)
  • OS benefit: 2.6 months gain (HR 0.64,95% CI 0.46-0.89)
  • ESMO-MCBS score: 3 (Form 2a)
Evidence from TROPIC Trial:
  • Comparison: Cabazitaxel vs. mitoxantrone (both with prednisone)
  • OS benefit: 2.4 months gain (HR 0.70,95% CI 0.59-0.83)
  • ESMO-MCBS score: 2 (Form 2a)

Alternative Systemic Therapies in mCRPC

Abiraterone + Prednisone

Post-Docetaxel Setting (COU-AA-301):

  • OS benefit: 4.6 months gain (HR 0.74,95% CI 0.64-0.86)
  • ESMO-MCBS score: 4 (Form 2a)

Chemotherapy-Naïve Setting (COU-AA-302):

  • OS benefit: 4.4 months gain (HR 0.81,95% CI 0.70-0.93)
  • ESMO-MCBS score: 2 (Form 2a)

Enzalutamide

Post-Docetaxel (AFFIRM):

  • OS benefit: 4.8 months gain (HR 0.53-0.75)
  • Quality of life: Improved
  • ESMO-MCBS score: 4 (Form 2a)

Pre-Chemotherapy (PREVAIL):

  • PFS benefit: >12 months gain (HR 0.15-0.23)
  • ESMO-MCBS score: 4 (Form 2b)

Treatment Sequencing Algorithm

Step 1: Initial mCRPC After ARPI Failure

  • If chemotherapy-naïve and fit: Docetaxel + prednisone/prednisolone
  • If prior docetaxel in hormone-sensitive setting: Consider cabazitaxel or alternative ARPI (though CARD trial favors cabazitaxel)

Step 2: After First Taxane Progression

  • If docetaxel was first-line: Cabazitaxel + prednisone/prednisolone (CARD trial supports this over ARPI switching)
  • Alternative: Abiraterone or enzalutamide if not previously used

Step 3: After Both ARPI and Taxane Exposure

  • If PSMA-positive on imaging: 177Lu-PSMA-617 radioligand therapy 1
  • If BRCA1/2 or HRR mutations: Consider PARP inhibitors (olaparib mentioned in guidelines)

Step 4: Subsequent Lines

  • Remaining taxane if not yet used
  • Clinical trial enrollment
  • Best supportive care with palliative intent

Critical Implementation Points

Common Pitfalls to Avoid:

  1. ARPI-to-ARPI switching: The CARD trial demonstrates that cabazitaxel is superior to switching from one ARPI to another ARPI in patients who have progressed on prior ARPI therapy 1

  2. Premature use of 177Lu-PSMA-617: Current ESMO guidelines require both prior ARPI AND taxane exposure before radioligand therapy. Emerging evidence suggests earlier use may be beneficial, but this is not yet reflected in the 2023 ESMO recommendations 2

  3. Missing PSMA-PET imaging: PSMA-positivity must be confirmed before considering radioligand therapy

  4. Toxicity monitoring: 177Lu-PSMA-617 has higher grade 3 adverse events (52.7%) compared to standard care (38%), requiring careful patient selection and monitoring 1

Strength of Evidence:

All recommendations are based on Level 1 evidence from randomized controlled trials with ESMO-MCBS scores ranging from 2-4, indicating clinically meaningful benefits. The 177Lu-PSMA-617 recommendation is particularly robust with an ESMO-MCBS score of 4m 1.

Note on Neuroendocrine Tumors

The provided ESMO guidelines do not contain recommendations for well-differentiated neuroendocrine tumors. The evidence presented is exclusively focused on prostate cancer management. For neuroendocrine tumor guidance, separate ESMO guidelines specific to gastroenteropancreatic or other neuroendocrine neoplasms would need to be consulted.

References

Related Questions

What novel therapies are recommended for advanced prostate cancer based on molecular biomarkers such as homologous recombination repair gene alterations, PSMA positivity, and microsatellite instability‑high/mismatch repair deficiency?
What is the definition of metastatic castrate‑resistant prostate cancer (mCRPC)?
Should a RadioMan Technician with occupational exposure to contaminated water, diesel and gasoline exhaust, solvents, lead‑acid batteries, high‑decibel noise, asbestos, and chemical‑resistant coating (CARC) be considered at increased risk for prostate cancer and therefore undergo annual prostate cancer screening with digital rectal exam and prostate‑specific antigen testing?
What is the exact administration protocol for lutetium-177 PSMA-617 (Lu-177 PSMA-617), including dose, infusion duration, pre‑treatment laboratory requirements, hydration, anti‑emetic prophylaxis, post‑infusion monitoring, radiation‑safety instructions, and cycle schedule?
For a 72-year-old man with metastatic castration‑resistant prostate cancer involving bone, liver, and lung, PSMA‑low disease, and progression after two androgen receptor pathway inhibitors, docetaxel, cabazitaxel, and ^177Lu‑PSMA‑617, which statement about novel antibody‑drug conjugate strategies presented at ASCO 2026 is most accurate?
Does an 8-year-old require a tetanus booster after removal of a foreign body from the arm following a bicycle accident?
What is the appropriate management for a 10-year-old male with a two-week history of cough and cold?
What are suitable alternative antibiotics to co‑amoxiclav (co‑amoxiclav) for a child?
According to ESMO guidelines, in a man with metastatic castration‑resistant prostate cancer who has progressed on androgen‑signaling blockade, what criteria determine the choice between ^177Lu‑PSMA‑617 radioligand therapy and taxane chemotherapy (docetaxel or cabazitaxel)?
How long should a woman wait after an uncomplicated miscarriage before trying to conceive again?
What is the appropriate management for a patient admitted with severe hypercalcemia (serum calcium 15.6 mg/dL) on a 5% dextrose infusion at 125 mL/hour whose calcium continues to rise to 15.8, 16.1, and now 16.4 mg/dL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.